Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies, cell therapies, and vaccines. Headquartered in Pennsylvania, the company primarily targets rare and underserved eye diseases, including inherited retinal disorders that cause progressive vision loss. Ocugen is distinctive for its "modifier gene therapy" platform, which aims to treat multiple genetic mutations with a single gene-agnostic approach rather than targeting individual gene defects. The company's lead clinical programs include OCU400 for retinitis pigmentosa and Leber congenital amaurosis, as well as OCU410 and OCU410ST for geographic atrophy and Stargardt disease. Beyond ophthalmology, Ocugen's pipeline features NeoCart, a regenerative cell therapy for knee cartilage repair, and an inhaled mucosal vaccine platform targeting respiratory viruses like COVID-19 and influenza. The company operates primarily in the United States and relies on strategic partnerships and licensing agreements to advance its clinical trials and manufacturing capabilities.
